Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galantamine + trospium is a combination of two small molecule drugs used together primarily in elderly patients who have both Alzheimer's disease (AD) and urge urinary incontinence (UUI). Galantamine is a reversible, competitive inhibitor of acetylcholinesterase, increasing acetylcholine levels and also acting as an allosteric modulator of nicotinic cholinergic receptors. It is approved for the treatment of mild to moderate dementia associated with Alzheimer's disease. Trospium is an antimuscarinic agent that relaxes bladder smooth muscle by antagonizing muscarinic acetylcholine receptors, thereby reducing symptoms of overactive bladder such as urgency and urge incontinence. The combination has been studied for its effects on cognition and urinary symptoms in elderly patients with both AD and UUI; evidence suggests it can be recommended for management of these coexisting conditions[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on galantamine + trospium.